Pfizer (PFE)
The desk's stance
On our research list, not on the slate.
What the company does
The post-COVID giant confronting a steep patent cliff ($21B+ losing exclusivity through 2028), betting big on its Metsera acquisition with 10 Phase 3 trials initiated for berobenatide (MET-097i) targeting a 2028 obesity launch.
Outlook: Raised full-year 2026 revenue guidance to $60.5B–$62.5B on non-COVID portfolio strength (+18% in newly launched/acquired products), while targeting $9.7B in net cost savings through 2029 to offset patent expiries.
In short: Biopharmaceuticals and vaccine developer. Category: Big Pharma Dividend Turnaround. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $27.49, computed Oct 18, 2026 (confidence: medium).
How we got there: 70% analyst leg $27.49 (4 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $44.79 (15.52× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street. 1 analyst target has no linked source and is shown but not counted.
G-Street Score: 50 out of 100 (Weak).
- Top-line growth & guidance: 7 of 32
- Margin power: 12 of 15
- Revenue visibility & quality: 3 of 11
- Profitability & balance sheet: 18 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 5 of 12
Our current thesis
Updated Oct 18, 2026
The thesis
- Discounted 10.2x forward P/E multiple and ~5.8% dividend yield provide defensive downside protection.
- Commercial execution across Seagen oncology assets and Eliquis stabilizes post-COVID base revenue.
- Multi-billion-dollar enterprise cost realignment programs continue to unlock operating margin efficiency.
Risks
- Patent cliffs on Eliquis and Vyndaqel threaten significant revenue erosion through 2028.
- Substantial $51.8B net debt burden constrains capital allocation flexibility and large-scale M&A.
- Significantly lags peers LLY and ABBV in organic top-line growth and margin expansion.
What we're watching
- Q3 2026 financial results and full-year guidance revision on November 3, 2026.
- Phase 3 clinical trial readout for prostate cancer therapy mevrometostat in late 2026.
- Phase 2 clinical data updates for Metsera-partnered obesity candidates expected by late 2026.
Latest
Pfizer trades near its 52-week high at $29.58 (10.2x forward P/E, ~5.8% yield) ahead of Q3 earnings on November 3, 2026. Commercial momentum across Padcev, Nurtec, and Eliquis drove Q2 revenue up 2.6% YoY to $15.03B, though GAAP printed a -$248M loss due to restructuring charges. An elevated $51.8B net debt burden and imminent patent expirations on key blockbusters cap near-term multiple expansion.
Key numbers
As of Oct 16, 2026: market cap $168.6B · revenue growth +2.6% year over year · gross margin 74.7% · net margin 6.8% · forward P/E 10.2 · next earnings Nov 3, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- JPMorgan, Neutral: $30 target (October 2026). Source: www.tipranks.com
- Bank of America, Neutral: $29 target (October 2026). Source: www.tipranks.com
- Cantor Fitzgerald, Neutral: $28 target (October 2026). Source: www.marketbeat.com
- Morningstar, Hold: $32 target (August 2026). Source: www.morningstar.com
On the Gainz Lab maps
Who it does business with
- Pfizer competes with Eli Lilly — The $10B gatecrash. Pfizer is running 10 Phase 3 trials for Metsera's berobenatide (MET-097i), targeting a 2028 obesity launch to replace patent cliff revenues.
- Pfizer partners with Bristol Myers Squibb — Eliquis JV. The Eliquis alliance generates massive cash flow for both, but impending patent loss forces both to fund replacement pipelines.
- Pfizer partners with BioNTech — Comirnaty JV. The COVID vaccine partnership that minted both companies — now a maturing cash flow baseline as BioNTech pivots to oncology.